Clinical Trial Update: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating navitoclax plus ruxolitinib versus best available therapy to assess spleen volume changes in adults with relapsed/refractory mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Navitoclax (navitoclax)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: AbbVie | Conditions: Myelofibrosis (MF) | Phase 3 | Status: ACTIVE_NOT_RECRUITING